Viral Inactivation Market

Global Viral Inactivation Market Size (2024 to 2029)

The global viral inactivation market is forecasted to be worth USD 1156.9 million by 2029 from USD 636.3 million in 2024, growing at a CAGR of 12.7% between 2024 to 2029.

Viral Inactivation is the procedure in which viral cells are killed or made inactive. This procedure is primarily performed to enhance safety and prevent viruses in the sample from contaminating the desired product. The virus may be present in the final product but in an inactive form. The range of inactivation techniques is performed chiefly in food and blood plasma industries to protect them from viral activity. Viral Inactivation is achieved by treating with dry heat, decreasing the pH to 4, solvent/detergent usage, irradiation by UV rays, and pasteurization.

Viral Inactivation using solvents and detergents is the most used in the blood plasma industry; however, it is effective only for viruses enveloped by lipid molecules.

The detergents/solvents interact with the lipid molecules in which viruses are present, thus rendering them ineffective as they cannot survive without lipid molecules. Pasteurization is effective when the proteins which are to be protected are more thermally resistant than the viruses. Similarly, lowering pH is effective when the molecules that are to be protected are more resistant than viruses. UV radiations cause damage to the DNA of living cells by creating nucleic acid dimers, thus affecting the life cycle and reproduction processes.

MARKET DRIVERS

The rising focus of R&D in life sciences and swift growth in pharmaceuticals and biotechnology industries and the rise of chronic diseases are majorly promoting the growth of the global viral inactivation market.

In addition, the rising support of the government in the biotechnology and pharmaceuticals sectors and the launch of new drugs, among others, are boosting the global market growth. The growing need for safety protocols in the life science fields is expected to help the market grow. Furthermore, the growing stringent government regulations with drug testing and manufacturing approval have led to more demand for proper viral Inactivation in drug discovery and development.

The rising investments in the life sciences industry, increased drug releases and approvals, and government support for the pharmaceutical and biopharmaceutical sectors in terms of funding are further propelling the global viral inactivation market.

Rise in the global prevalence of chronic diseases such as cancer, autoimmune disorders, and other diseases, as well as an increase in healthcare spending, including an improving research and development investment climate, an increased risk of cell culture pollution, advances in nanofiltration technology, are driving the viral inactivation market. In addition, FDA approval leads to the commercialization of new medicines and helps market expansion.

Increased outsourcing of pharmaceutical products and growth in developing markets would open up new opportunities for the viral inactivation market.

In addition, the medical industry's technological evolution is driving up demand for viral inactivation methods and developing new and improved treatments to combat the increase in many diseases. Rising drug advances are also fueling the viral inactivation market's growth.

MARKET RESTRAINTS

The global viral inactivation market is restrained by a smaller number of skilled workers and the incidence of solid consolidation.

Furthermore, high costs associated with the manufacture of biosimilar products and high levels of competition are expected to restrict demand development in the forecast period. The shortage of qualified workers would challenge the growth of the viral inactivation market. In addition, some problems with the virus inactivation process, such as virus aggregate formulation, protein crosslinking, and protein denaturation and degradation, limit its market development even further.

Impact of COVID-19 on the global viral inactivation market

COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Due to the strict implementation of the lockdown, nearly all industries were shut down and adversely impacted. As a result, the Viral Inactivation Market was positively impacted during the pandemic. Furthermore, since Viral Inactivation is used to kill dormant viral cells, the viral inactivation technique was done on the laboratory workers handling materials containing SARS-CoV-2 to improve immunity, which accelerated the global viral inactivation market growth during the pandemic.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Viral Inactivation Market Analysis By Method

The largest market share is held by the solvent/detergent method since it requires less investment, is easy to use, and provides a high degree of Inactivation of viruses. It is also a trusted and established method for viral Inactivation, which has been used for 30 years in the research industry.

However, due to its efficiency, the UV radiation segment is also expected to show significant growth during the forecast period. UV radiation is a natural virus that kills the virus by changing its chemical composition. Moreover, solar exposure is a powerful germicide in nature; therefore, the strength of UV radiation is expected to fuel this market segment.

Global Viral Inactivation Market Analysis By Product

Due to their widespread use by pharmaceutical and biopharmaceutical firms, kits and reagents accounted for the largest market share based on the product. In addition, the increasing research and development activities in the viral inactivation processes are helping augment the market's growth.

However, a wide range of viral inactivation systems is used in the process, thus promoting the segment's development. Furthermore, viral inactivation systems are equipped with automated systems to perform all types of inactivation with minimal manual input helping fast and efficient processing, thus increasing in popularity.

Global Viral Inactivation Market Analysis By Application

The vaccines and therapeutics segment is predicted to have the largest share of the global market during the forecast period due to increased government funding to promote the use of biologics to cure diseases and advances in biologics development. In addition, the rising need for better therapeutics and vaccinations is expected to help develop the market segment.

However, the stem cell products segment is also expected to show growth due to the rising interest and research towards stem cell research and development. In addition, there are also reports of cross-contamination of stem cells among patients leading to the requirement for better viral inactivation/clearance for stem cells.

Global Viral Inactivation Market Analysis By End-User

The demand for viral Inactivation was dominated by the pharmaceutical and biotechnology industries. This is primarily due to the expanded use of these goods for drug production and processing, fuelling the segment's expansion. In addition, the rising establishment of biotechnology and pharmaceuticals due to the rising research and development in the viral inactivation market is helping the segment's progress.

However, CROs are lately developing as the number of contracts for various research processes. CROs are like third-party service providers who help major industries with various research processes in a hassle-free and easy procedure. Increasing FDA guidelines about drug testing safety and releasing CROs is a central helping hand.

REGIONAL ANALYSIS

the North American viral inactivation market is predicted to account for the most significant global market share during the forecast period. The North American viral Inactivation Market was valued at USD 152.42 million in 2020, and by 2025, the market was estimated to be growing at a CAGR of 13.1% to reach USD 282.06 million. The rapid pharmaceutical and biotechnology growth is driving the North American Viral Inactivation Market. In terms of sales, the United States has the highest market share in North America. This is primarily due to improved hospital systems, sophisticated equipment and technology, and rising healthcare costs. In addition, the rising incidence of chronic diseases and the growing focus on research and development in life sciences boost the US Viral Inactivation Market. For instance, the American Cancer Society 2019 reported 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the United States only. Moreover, the government's rising support to develop the biotechnology and pharmaceutical sectors is fueling market growth. Canada is increasing predominantly during the forecast period owing to the rise in pharmaceutical production.

The size of the Europe Viral Inactivation Market was valued at USD 120.66 million in 2020. By 2025, the market is estimated to reach USD 213.60 million to grow at a CAGR of 12.1% during the forecast period. The European Viral Inactivation Market is driven by the increasing prevalence of chronic diseases and rapid growth in the pharmaceutical and biotechnology industries. Furthermore, the demand is boosted by a surge in new drug releases and increased research and development sectors in the life sciences. The rising incidence of chronic diseases and high pharmaceutical and biotechnology growth drive the European Viral Inactivation Market.

Moreover, the rise in new drug launches and increased research and development industries in life sciences boost the market. The presence of several market players in Europe is boosting the European Viral Inactivation Market. The UK and Germany are the major contributors to the European Viral Inactivation Market.

KEY PLAYERS IN THE GLOBAL VIRAL INACTIVATION MARKET

Some of the major players in the global viral inactivation market profiled in the report are Clean Cells, Charles River Laboratories International Inc, Danaher Corporation, Merck KGaA, Parker Hannifin, Red Source Technologies, Sartorius AG, SGS S.A, Texcell Inc, Viral Inactivated Plasma Systems SA, and Wuxi Pharma Tech Inc.

RECENT HAPPENINGS IN THE GLOBAL MARKET

• In March 2022, Thermofisher, a life sciences company, developed a non-hazardous formula to rapidly inactivate and transport the SARS-Cov-19 virus. This efficient and safe method supported the research that needed to be conducted on the virus samples and the development of vaccines. The formula was called the Inhibisure viral inactivation medium formula. Aside from the application in the covid situation, the formulation is also expected to help future transports of viruses.
• In October 2022, Imunon, inc. has recently published the results of its experimentation on apes with a newer vaccination procedure called the PLACCINE vaccine, which is expected to work similarly to an mRNA vaccine. The recent results of the test through bronchoalveolar lavage and quantitative PCR have shown a more significant 90% viral inactivation. The virus being examined was the SARS-Cov-2 Alpha variant, and the results have been promising from the clinical-stage drug development company.
• In April 2022, in a research collaboration between Hokkaido University and Shinobi, a biopharmaceutical company, a test series for a COVID-19 antiviral development, a promising result of virus clearance was found in the tests conducted in the Asian regions. The phase II b trial of S-217622 resulted in the most significant virus clearance of SARS-CoV-2 patients in Japan and South Korea. In addition, the 428 tested patients showed improved results during clinical trials, ensuring positive outcomes from the experiment.

DETAILED SEGMENTATION OF THE GLOBAL VIRAL INACTIVATION MARKET INCLUDED IN THIS REPORT

This research report on the vital global signs monitoring market has been segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment.

By Method

• Solvent/Detergent Method
• Pasteurization
• UV Radiation
• Microwave Heating
• High-Energy Light

By Product

• Kits and Reagents
• Services
• Accessories
• Viral Inactivation Systems

By Application

• Vaccines and Therapeutics
• Stem Cell Products
• Cell Culture
• Gene Therapy
• Blood & Blood Products

By End User

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutes

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa